85387-44-6

Basic information

• Product Name: 1-BENZYL-3-HYDROXYMETHYLPIPERIDINE
• Synonyms: 1-BENZYL-3-HYDROXYMETHYLPIPERIDINE;(1-benzylpiperidin-3-yl)methanol hydrochloride;3-piperidinemethanol, 1-(phenylmethyl)-;(1-benzylpiperidin-3-yl)methanol(SALTDATA: FREE)
• CAS NO: 85387-44-6
• Molecular Formula: C₁₃H₁₉NO
• Molecular Weight: 205.3
• Mol File: 85387-44-6.mol

Chemical Properties

• Boiling Point: 294.068 °C at 760 mmHg
• Flash Point: 123.378 °C
• Appearance: /
• Density: 1.056 g/cm³
• PKA: 14.93±0.10(Predicted)
• CAS DataBase Reference: 1-BENZYL-3-HYDROXYMETHYLPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL-3-HYDROXYMETHYLPIPERIDINE(85387-44-6)
• EPA Substance Registry System: 1-BENZYL-3-HYDROXYMETHYLPIPERIDINE(85387-44-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 85387-44-6(Hazardous Substances Data)

Usage

Uses

1-Benzyl-3-Hydroxymethylpiperidine is used as a chemical intermediate for the synthesis of various pharmaceuticals and other synthetic compounds. Its aromatic amine nature and solubility in organic solvents make it a promising candidate for further research and development in the chemical and pharmaceutical industries.
Used in Pharmaceutical Industry:
1-Benzyl-3-Hydroxymethylpiperidine is used as a building block for the development of new drugs, particularly in the synthesis of compounds with potential therapeutic applications. Its unique structure and reactivity can be exploited to create novel molecules with desired pharmacological properties.
Used in Chemical Research:
1-Benzyl-3-Hydroxymethylpiperidine is used as a subject for further research in the field of organic chemistry. Its properties and reactivity can be studied to gain insights into the behavior of similar compounds and to develop new synthetic strategies and methodologies.
Note: Since the provided materials do not contain specific information about the exact chemical properties, uses, or safety profile of 1-Benzyl-3-Hydroxymethylpiperidine, the above uses are based on the general characteristics of benzylpiperidines and aromatic amines. Further research and investigation would be required to confirm its specific applications and potential.

Upstream product

• 4606-65-9 3-(hydroxymethy)piperidine 
• 100-44-7 benzyl chloride 
• 98-88-4 benzoyl chloride 
• 614-18-6 3-pyridinecarboxylic acid ethyl ester 
• 72551-53-2 ethyl 1-benzylpiperidine-3-carboxylate 
• 100-52-7 benzaldehyde 
• 100-39-0 benzyl bromide 

Downstream Products

• 1610553-66-6 C₁₉H₂₃N₃O₂ 
• 1564315-39-4 C₂₀H₂₃N₃O₃ 
• 1564315-32-7 C₂₀H₂₃N₃O₃ 
• 1564315-25-8 C₂₀H₂₃N₃O₃ 
• 1564315-24-7 C₂₂H₂₇N₃O₅ 
• 1610550-12-3 C₂₀H₂₄N₂O₂ 
• 1610549-56-8 C₂₀H₂₄N₂O₂ 
• 1610549-17-1 C₂₀H₂₄N₂O₂ 
• 1564315-36-1 C₂₀H₂₄N₄O₂ 
• 109859-83-8 N-benzyl-3-(bromomethyl)-piperidine 
• 119919-05-0 N-benzyl-3-(benzenesulphonyloxymethyl)-piperidine 

Relevant articles and documents

N-alkylpiperidine carbamates as potential anti-Alzheimer's agents

Compounds capable of interacting with single or multiple targets involved in Alzheimer's disease (AD) pathogenesis are potential anti-Alzheimer's agents. In our aim to develop new anti-Alzheimer's agents, a series of 36 new N-alkylpiperidine carbamates was designed, synthesized and evaluated for the inhibition of cholinesterases [acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)] and monoamine oxidases [monoamine oxidase A (MAO-A and monoamine oxidase B (MAO-B)]. Four compounds are very promising: multiple AChE (IC50 = 7.31 μM), BChE (IC50 = 0.56 μM) and MAO-B (IC50 = 26.1 μM) inhibitor 10, dual AChE (IC50 = 2.25 μM) and BChE (IC50 = 0.81 μM) inhibitor 22, selective BChE (IC50 = 0.06 μM) inhibitor 13, and selective MAO-B (IC50 = 0.18 μM) inhibitor 16. Results of enzyme kinetics experiments showed that despite the carbamate group in the structure, compounds 10, 13, and 22 are reversible and non-time-dependent inhibitors of AChE and/or BChE. The resolved crystal structure of the complex of BChE with compound 13 confirmed the non-covalent mechanism of inhibition. Additionally, N-propargylpiperidine 16 is an irreversible and time-dependent inhibitor of MAO-B, while N-benzylpiperidine 10 is reversible. Additionally, compounds 10, 13, 16, and 22 should be able to cross the blood-brain barrier and are not cytotoxic to human neuronal-like SH-SY5Y and liver HepG2 cells. Finally, compounds 10 and 16 also prevent amyloid β1–42 (Aβ1–42)-induced neuronal cell death. The neuroprotective effects of compound 16 could be the result of its Aβ1–42 anti-aggregation effects.

Design, synthesis, and characterization of novel, nonquaternary reactivators of GF-inhibited human acetylcholinesterase

The goal of this research was to identify structurally novel, non-quaternarypyridinium reactivators of GF (cyclosarin)-inhibited hAChE that possess the capacity to mediate in vitro reactivation of GF-inhibited human acetylcholinesterase (hAChE). New compounds were designed, synthesized and assessed in GF-inhibited hAChE assays. Structure activity relationships for AChE binding and reactivation of GF-inhibited hAChE were developed. Lead compounds from two different chemical series, represented by compounds 17 and 38, displayed proficient in vitro reactivation of GF-inhibited hAChE, while also possessing low inhibition of native enzyme.

HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS

Compounds of formula (I) Q-L-W-C(=X)-Z-P wherein Q is an amine of the formula-N (R1)(R2); L is an alkyl or heterocyclyl-alkyl linker; W is a 6-or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 which are linked to groups L and C(X) respectively and Y1 and Y2 are independently selected from N and C; X is O, N, N-CN or S; Z is NR 3; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C-C chemokine mediated conditions.

Novel 2-amino-1,4-dihydropyridine calcium antagonists. II. Synthesis and antihypertensive effects of 2-amino-1,4-dihydropyridine derivatives having N,N-dialkylaminoalkoxycarbonyl groups at 3- and/or 5-positions

Novel 2-amino-1,4-dihydropyridine derivatives I, which contain N,N-dialkylaminoalkoxycarbonyl groups at the 3- and/or 5-position, were synthesized and their antihypertensive effects were evaluated in spontaneously hypertensive rats. Remarkably prolonged duration of antihypertensive action was observed when a tertiary amino group was introduced into either the 3- or 5-ester side-chain of the 1,4-dihydropyridine ring. In particular, the compounds containing cyclic amino moieties at the 3-position showed greater potency than those with acyclic amino moieties. Chemical modification studies indicated that the two ester side-chains of 1,4-dihydropyridine at the 3- and 5-position might function in a different manner in relation to the antihypertensive activities. 3-(1-Benzhydrylazetidin-3-yl) 5-isopropyl 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxyl ate, I-43 (CS-905), exhibited potent and long-lasting antihypertensive effects with gradual onset of action, and is a promising candidate as an antihypertensive drug.

ETHER DERIVATIVES OF ALKYL PIPERIDINES AND PYRROLIDINES AS ANTIPSYCHOTIC AGAENTS

Novel unsaturated ether derivatives of alkyl piperidine and pyrrolidine compounds, pharmaceutical compositions containing them, methods of preparation and methods of using these compounds as antipsychotic agents are disclosed.

Novel piperidine σ receptor ligands as potential antipsychotic drugs

σ receptor ligands represent a new class of potential antipsychotic drugs. This paper presents the structure-activity relationships leading to novel disubstituted piperidine σ ligands, which have little or no affinity for dopamine D2 receptors. Selectivity for σ sites over dopamine D2 or serotonin 5-HT2 receptors appears to be governed by the chemical nature of the piperidine nitrogen substituent, its distance from the basic nitrogen, and its orientation relative to the other piperidine substituent. Several of these compounds have good oral potency in some animal models used to evaluate potential antipsychotic drugs. The N-cyclopropylmethyl ketones and ethers (e.g. 6i (DuP 734), 6q, 18a, and 18n) have the best in vivo potency. Compounds 6i (DuP 734) and 6q did not cause catalepsy in the rat, even at very high doses. On the basis of the pharmacology profiles of these σ ligands, we propose these compounds may be effective antipsychotic drugs, which do not induce extrapyramidal side effects or tardive dyskinesia.

Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them

Disclosed are new cyclic amine derivatives of the formula I STR1 wherein the substituents are defined in the specification. These compounds are useful as for treating sinus tachycardia.

3-piperidine Derivatives. Synthesis and Antidepressant Activity

The 3-piperidine derivatives 3-5 were synthesized and screened as potential antidepressant agents by the reserpine interaction test in mice and the evaluation of reuptake inhibition of biogenic amines in pig brain synaptosomal fractions.In addition, their anticonvulsant activity, tested by pentylenetetrazole antagonism, and approximate acute toxicity were evaluated.In vivo and in vitro tests showed that compounds 3 and 5 possess a biological activity comparable to that of the antidepressant drug viloxazine (2).